Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xenotransplantation

Executive Summary

Unanimous approval given by the Biological Response Modifiers Advisory Committee July 30 to a report issued by the Xenotransplantation Subcommittee following its Dec. 7 meeting. At issue was the subcommittee's recommendation that FDA should allow xenotransplant clinical trials; FDA's decision to issue a guidance, due in late 1998, that may streamline clinical trials by establishing requirements for biological assays; the establishment of an electronic registry that would track recipients from transplant to death and also track donor sources; the establishment of a national xenotransplantation advisory committee to keep the public informed; and the committee's desire for worldwide harmonization of regulations governing xenotransplantation

Latest Headlines
See All
UsernamePublicRestriction

Register

PS032610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel